These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9566460)
21. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven? Briggs AH; Levy AR Pharmacoeconomics; 2006; 24(11):1079-86. PubMed ID: 17067193 [TBL] [Abstract][Full Text] [Related]
22. Better analysis for better decisions: has pharmacoeconomics come of age? Drummond M; Sculpher M Pharmacoeconomics; 2006; 24(2):107-8. PubMed ID: 16460132 [No Abstract] [Full Text] [Related]
24. Drug development means economics in the end. Senn S BMJ; 2001 Mar; 322(7287):675. PubMed ID: 11291652 [No Abstract] [Full Text] [Related]
25. Pharmaceuticals and medical devices: business practices. ; Steiner DJ Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396 [No Abstract] [Full Text] [Related]
26. Ex post value reimbursement for pharmaceuticals. Gravelle HS Med Decis Making; 1998; 18(2 Suppl):S27-38. PubMed ID: 9566465 [TBL] [Abstract][Full Text] [Related]
27. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Postma MJ; Boersma C; Gansevoort RT Nephrol Dial Transplant; 2008 Apr; 23(4):1103-6. PubMed ID: 17210586 [No Abstract] [Full Text] [Related]
28. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief. Chaps NA Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557 [No Abstract] [Full Text] [Related]
29. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Pavenik N Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303 [TBL] [Abstract][Full Text] [Related]
31. Qualitative factors underlying the successful investment in new ophthalmic pharmaceutical products in the United States. Stewart WC; Chaney PG; Stewart JA; Kruft B; Nelson LA Acta Ophthalmol; 2013 Sep; 91(6):e496-7. PubMed ID: 23834660 [No Abstract] [Full Text] [Related]
32. Pharmaceuticals and medical devices: business practices. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448 [No Abstract] [Full Text] [Related]
33. Applying patient outcomes and pharmacoeconomics in patient care. Proceedings of a conference. Boston, Massachusetts, September 1994. Am J Health Syst Pharm; 1995 Jul; 52(14 Suppl 3):S1-5. PubMed ID: 7552910 [No Abstract] [Full Text] [Related]
34. Is there a need for an independent centre for pharmacoeconomics in the UK? Walley T; Edwards RT Pharmacoeconomics; 1994 Feb; 5(2):93-100. PubMed ID: 10146902 [No Abstract] [Full Text] [Related]
35. Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track? Pausjenssen AM; Detsky AS Med Decis Making; 1998; 18(2 Suppl):S19-22. PubMed ID: 9566463 [No Abstract] [Full Text] [Related]
36. The economics of contraceptives R&D. Djerassi C Science; 1996 Jun; 272(5270):1858-9. PubMed ID: 8658149 [No Abstract] [Full Text] [Related]